Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Manifestations in Post-COVID-19 Patients
Author(s): Angela Cozma , Violeta Briciu , Adela Viviana Sitar-Tăut , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
William H Sauer
Research Area(s) / Expertise:
Personal History Dr William Henry Sauer is a Cardiologist and a Cardiac Electrophysiologist in Boston, Massachusetts. Academic History He earned his BA in Biology and BS in Bioengineering in 1995 and his M.D. in 1999 from the University of Pennsylvania.2 He then completed his Internal Medicine Residency (1999 - 2001), Cardiovascular Disease Fellowship (2001 - 2003) and Clinical… View more
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Added: 4 months ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,… View more

Cardiovascular Kidney Metabolic

Heart Failure
Multidisciplinary Team Working
Added: 1 year ago
This episode explores what an ideal hypertrophic cardiomyopathy (HCM) “dream team” looks like, how it would function and the challenges of making it a reality. Prof Juan Pablo Kaski (Professor of Paediatric Inherited Cardiovascular Medicine at University College London, London, UK) is joined by Dr Elena Biagini (Cardiologist at Sant'Orsola Hospital, Bologna, IT) and Dr Jodie Ingles (Cardiac… View more

Heart Failure
Mavacamten Fails to Meet Primary Endpoints in Non-obstructive Hypertrophic Cardiomyopathy
Added: 9 months ago Source:  Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England… View more

Guidelines & Statements

Heart Failure
Paul Foley
Job title: Consultant Cardiologist
Dr Paul Foleyis a consultant cardiologist at The Great Western Hospitalsin Swindon. Dr Foley specialises in HF and rhythm issues. View more
Michael S Firstenberg
Research Area(s) / Expertise: Job title: Director of Research and Special Projects
Personal History Dr Michael Sol Firstenberg was born in 1968 and grew up in northeast Ohio.8 He is a Cardiothoracic Surgeon and Director of Research and Special Projects at the William Novick Global Cardiac Alliance and Assistant Professor of Surgery and Adjunct Assistant Professor of Integrative Medical Sciences at Northeast Ohio Medical University. Outside of work, Dr Firstenberg… View more
Jeroen J Bax
Research Area(s) / Expertise: Job title: Director, Echo Laboratory & Non-invasive Imaging, Department of Cardiology
Personal History Dr Jeroen Joost Bax was born in Amsterdam and was the first member of his family to study medicine. As a professor, Dr Bax has mentored over 60 international PhD students in his cardiac imaging research centre at Leiden University Medical Center (LUMC) and his students have achieved prominent positions at medical institutions throughout the world.1 “I care a lot about the… View more
Joseph G Akar
Research Area(s) / Expertise:

Atrial Fibrillation

Electrophysiology & Arrhythmia

Atrial Arrhythmias
Personal History Dr Joseph Gabriel Akar was born in January 1971 and speaks Arabic, English and French.9 He is an Associate Professor of Medicine in the Section of Cardiology at the Yale University School of Medicine. He is currently Chief of Cardiac Electrophysiology and Director of the Electrophysiology Laboratory and the Complex Ablation Program at Yale-New Haven Hospital. … View more
Low-Dose Triple Pill vs Monotherapy for Hypertension
Added: 4 months ago Source:  Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic